BCH BM - Bristol Myers Ex Devel

BMYB34 Stock  BRL 355.25  12.45  3.63%   

Insider

BCH BM is Ex Devel of Bristol Myers Squibb
Age 57
Phone212 546 4000
Webhttps://www.bms.com

Bristol Myers Management Efficiency

The company has return on total asset (ROA) of 0.0613 % which means that it generated a profit of $0.0613 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1846 %, meaning that it generated $0.1846 on every $100 dollars invested by stockholders. Bristol Myers' management efficiency ratios could be used to measure how well Bristol Myers manages its routine affairs as well as how well it operates its assets and liabilities.
Bristol Myers Squibb has accumulated 39.6 B in total debt with debt to equity ratio (D/E) of 159.7, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Bristol Myers Squibb has a current ratio of 3.8, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Bristol Myers until it has trouble settling it off, either with new capital or with free cash flow. So, Bristol Myers' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Bristol Myers Squibb sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Bristol to invest in growth at high rates of return. When we think about Bristol Myers' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

David WeberCharter Communications
67
David KlineCharter Communications
61
Neville RayT Mobile
60
Thomas AdamsCharter Communications
63
Michael SievertT Mobile
53
Yan ZengAutohome
55
Jennifer SmoterUnitedHealth Group Incorporated
N/A
Catherine BohigianCharter Communications
46
Gregory MaffeiCharter Communications
58
David EllenCharter Communications
58
Hong JiangAutohome
N/A
W ConnCharter Communications
50
Philipp KuckuckMAHLE Metal Leve
N/A
Zachary SopcakUnitedHealth Group Incorporated
N/A
John RexUnitedHealth Group Incorporated
61
Janice KapnerT Mobile
N/A
Quan LongAutohome
52
Jud HenryT Mobile
N/A
Craig JacobsonCharter Communications
66
Rupert BondyUnitedHealth Group Incorporated
61
Anita ChenAutohome
N/A
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York. BRISTOLMYERSDRN operates under Drug Manufacturers - Major classification in Brazil and is traded on Sao Paolo Stock Exchange. It employs 23300 people. Bristol Myers Squibb (BMYB34) is traded on Sao Paulo Exchange in Brazil and employs 41 people.

Management Performance

Bristol Myers Squibb Leadership Team

Elected by the shareholders, the Bristol Myers' board of directors comprises two types of representatives: Bristol Myers inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bristol. The board's role is to monitor Bristol Myers' management team and ensure that shareholders' interests are well served. Bristol Myers' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bristol Myers' outside directors are responsible for providing unbiased perspectives on the board's policies.
Jitendra Tyagi, Head India
Cari Gallman, VP Officer
David Elkins, Ex CFO
BCH BM, Ex Devel
Giovanni MD, Chairman CEO
Greg Meyers, Ex Officer
Ann Judge, Senior Vice President - Global Human Resources
Sandra Esq, Exec Counsel
Timothy Power, VP Relations
Christopher Boerner, Executive Vice President and Chief Commercial Officer

Bristol Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Bristol Myers a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Information and Resources on Investing in Bristol Stock

When determining whether Bristol Myers Squibb offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bristol Myers' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bristol Myers Squibb Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bristol Myers Squibb Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bristol Myers Squibb. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Please note, there is a significant difference between Bristol Myers' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bristol Myers is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bristol Myers' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.